News

Targeted Oncology2h
Adjuvant Nivolumab Shows Sustained Benefit in Esophageal/GEJ Cancer
Bonilla, MD, MSEd, discusses 5-year data from the phase 3 CheckMate 577 trial, presented at the 2025 ASCO Annual Meeting.
Targeted Oncology4h
QUILT-88 Study: Promising Survival in Pancreatic Cancer
The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment ...
Targeted Oncology7h
Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology1h
Lack of Comparative Trials in R/R MM Complicates Treatment Selection
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.
Targeted Oncology23h
Identifying Situations Where CTLA-4 Addition Improves NSCLC Outcomes
During a live event, Neal E. Ready, MD, and participants discussed what factors justify using PD-1 plus CTLA-4 inhibitor and ...
Targeted Oncology6h
Dr Klempner: ASCO 2025 GI Cancer Insights and News
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.